| n (%) |
44 (30%) |
101 (70%) |
— |
| Age (years), median (range) |
65 (42 to 79) |
66 (24 to 83) |
0.670 |
| Male gender, n (%) |
42 (96%) |
79 (78%) |
0.010 |
| Disease duration (years), median (range) |
16 (0 to 44) |
9 (0 to 50) |
0.011 |
| Delay to starting allopurinol (months), median (range) |
48 (0 to 312) |
— |
— |
| Length of treatment (months), median (range) |
120 (1 to 480) |
— |
— |
| Self‐reported adherence <90% |
7 (15%) |
— |
— |
| Serum urate (μmol/l), mean (SD) |
318 (66) |
434 (101) |
<0.001 |
| Serum urate >360 μmol/l, n (%) |
10 (23%) |
75 (75%) |
<0.001 |
| At least 1 attack in preceding year |
14 (32%) |
57 (57%) |
0.005 |
